NCI Pediatric In Vivo Testing Program Coordinating Center (U24 Clinical Trial Not Allowed)

Funding Opportunity RFA-CA-20-041 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is for a Coordinating Center for the NCI Pediatric in Vivo Testing Program (henceforth termed the Ped-In Vivo-TP). The main goal for the Ped-InVivo-TP is to use genomically-characterized pediatric cancer models to develop a rigorous preclinical testing system to generate reliable data that can be used to inform new agent prioritization decisions for childhood cancers. The Ped-In Vivo-TP has two parts: a) research teams for in vivo testing to determine the activity of pediatric anticancer drug candidates, supported under RFA-CA-20-037); and b) a Coordinating Center (RFA-CA-20-041, this FOA). The Ped-InVivo-TP is envisioned as a way for NCI to support the Foundation for the National Institutes of Health (FNIH)-organized Public-Private Partnership (PPP) for pediatric preclinical testing. The PPP is being developed to accelerate the pace and to broaden the scope of pediatric preclinical testing of agents being developed for adult cancer indications. Pharmaceutical companies and representatives of regulatory agencies will also participate in the PPP. The Program Director(s)/Principal Investigator(s) [PD(s)/PI(s)] of the Ped-InVivo-TP Research Teams and Coordinating Center will be expected to serve on the Scientific Advisory Committee (SAC) of the FNIH PPP and will contribute to the SAC with regards to the research opportunities in their areas of expertise....
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding